Floatz logo

3-IODOBENZYLGUANIDINE (123I)

Dementia

Mayo ClinicSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Dementia cohort.

Asset / SponsorPhaseRating
Risperidone
Hannover Medical School
Phase 4BBB
Citalopram
Hannover Medical School
Phase 4BBB
Escitalopram
Ohio State University
Phase 4BB
Memantine
Zealand University Hospital
Phase 4BB
Galantamine Hydrobromide
Janssen Pharmaceutica N.V., Belgium
Phase 3BB

View all 50 →

Same molecule, other indications

3-IODOBENZYLGUANIDINE (123I) is also rated in:

Lewy body dementiaActive
BB
Indicative · Phase 4
65 / 100
View asset →
REM sleep behavior disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →
cognitive disorderActive
B
Indicative · Phase 4
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →